Rifaximin is under clinical development by Alfasigma and currently in Phase III for Collagenous Colitis. According to GlobalData, Phase III drugs for Collagenous Colitis does not have sufficient ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

The tentative approval for ANDA 218862 was posted to the Drugs@FDA site. Stay Ahead of the Market:Discover outperforming stocks and invest ...

The company noted that there are currently limited suppliers of the treatment. Approval of Rifaximin, the IBS treatment, is tentative because the product is currently in litigation. "Amneal's ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a pharmaceutical company with a market capitalization of ...

To treat IBS-D, the typical dosage of rifaximin is 550 mg tablet three times per day for 14 days. If the diarrhea continues, a healthcare provider may prescribe up to two more rounds of treatment.

Forcing a struggling child to take any medicine can lead to vomiting or choking. Using a better technique can sometimes get rid of the child's resistance. Doctors can sometimes replace a bad-tasting ...

Beyond Cancer: Confronting the Challenges of Survivorship In this series, experts from Duke Cancer Institute discuss how the integration of cancer treatment and primary care is improving patient ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...